Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on June 6, 2025
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
GlobeNewswire
·
June 6, 2025
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
GlobeNewswire
·
June 6, 2025
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design …
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
GlobeNewswire
·
June 6, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report …
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing …
Enovis to Participate in Upcoming Investor Conferences
GlobeNewswire
·
June 6, 2025
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th …
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly …
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 6, 2025
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
GlobeNewswire
·
June 6, 2025
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …
OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert …
Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™
GlobeNewswire
·
June 6, 2025
TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments ( …
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
GlobeNewswire
·
June 6, 2025
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national …
American Botanical Council Acquires Full Rights to Steven Foster Photo Library
GlobeNewswire
·
June 6, 2025
Austin, Texas, June 06, 2025 (GLOBE NEWSWIRE) -- The nonprofit American Botanical Council (ABC) announces that it has obtained ownership rights to the entire collection of medicinal and aromatic plant photographs taken by the late botanist, author, and …
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
GlobeNewswire
·
June 6, 2025
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and communicated the …
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
GlobeNewswire
·
June 6, 2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 6 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in …
Press release: Transparency Notification from Shareholders
GlobeNewswire
·
June 6, 2025
Transparency Notification from Shareholders Ghent, Belgium – 6 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and …
Isha Foundation’s Meditation App Surpasses ChatGPT’s Launch Pace, Signals Global Demand for Digital Stillness
GlobeNewswire
·
June 6, 2025
Los Angeles, CA, June 06, 2025 (GLOBE NEWSWIRE) -- As artificial intelligence dominates headlines, one of the fastest-growing wellness apps is turning heads for a different reason: silence. The Isha Foundation recently launched Miracle of Mind, a free …